A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer

被引：0

作者：

Vukelja, S.

Rugo, H.

Vogel, C.

Borson, R.

Tan-Chiu, E.

Birkner, M.

Holden, S. N.

Klencke, B.

O'Shaughnessy, J.

Burris, H. A.

机构：

[1] Tyler Canc Ctr, Tyler, TX USA

[2] UCSF Comprehens Canc Ctr, San Francisco, CA USA

[3] Lynn Canc Inst, Boca Raton, FL USA

[4] St Louis Canc & Breast Inst, St Louis, MO USA

[5] Genentech Inc, San Francisco, CA 94080 USA

[6] Baylor Sammons Canc Ctr, Dallas, TX USA

[7] Sarah Cannon Canc, Nashville, TN USA

来源：

CANCER RESEARCH | 2009年 / 69卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：71S / 71S

页数：1

共 50 条

[41] BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Song, E.
Yao, H.
Wang, Y.
Zeng, Y.
Sun, M. L.
Zong, H.
Lin, R.
Wen, Z.
Ding, R. M.
Yu, J.
Xiao, S.
Wang, H.
Zhu, H.
Olivo, M. S.
Zhu, Y.
ANNALS OF ONCOLOGY, 2023, 34 : S478 - S479
[42] Bevacizumab plus trastuzumab for treatment of HER2+metastatic breast cancer
De Amuriza Chicharro, N.
Gastalver Martin, C.
Goyache Goni, M. P.
Cortijo Cascajares, S.
Garcia Munoz, C.
Ferrari Piquero, J. M.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 984 - 985
[43] AN ANTIBODY-DRUG CONJUGATE IS EFFECTIVE IN HER2-POSITIVE BREAST CANCER
不详
CANCER DISCOVERY, 2012, 2 (11) : 969 - 969
[44] Responses to Subsequent Anti-HER2 Therapy after Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer
Olson, E. M.
Lin, N. U.
DiPiro, P. J.
Najita, J.
Krop, I. E.
Winer, E. P.
Burstein, H. J.
CANCER RESEARCH, 2010, 70
[45] Predictors of survival in patients with HER2+metastatic breast cancer (MBC) treated with trastuzumab
Olson, E. M.
Najita, J. S.
Sohl, J.
Arnaout, A.
Winer, E. P.
Lin, N. U.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[46] Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer
Gupta, Manish
LoRusso, Patricia M.
Wang, Bei
Yi, Joo-Hee
Burris, Howard A., III
Beeram, Muralidhar
Modi, Shanu
Chu, Yu-Waye
Agresta, Samuel
Klencke, Barbara
Joshi, Amita
Girish, Sandhya
JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (05): : 691 - 703
[47] Population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of various covariates
Lu, D.
Girish, S.
Gao, Y.
Wang, B.
Yi, J-H
Guardino, E.
Samant, M.
Cobleigh, M.
Rimawi, M.
Conte, P.
Jin, J.
CANCER RESEARCH, 2012, 72
[48] Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer
Hayashi, Tetsutaro
Seiler, Roland
Oo, Htoo Zarni
Jaeger, Wolfgang
Moskalev, Igor
Awrey, Shannon
Dejima, Takashi
Todenhoefer, Tilman
Li, Na
Fazli, Ladan
Matsubara, Akio
Black, Peter C.
JOURNAL OF UROLOGY, 2015, 194 (04): : 1120 - 1131
[49] Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer
Olson, E. M.
Lin, N. U.
DiPiro, P. J.
Najita, J. S.
Krop, I. E.
Winer, E. P.
Burstein, H. J.
ANNALS OF ONCOLOGY, 2012, 23 (01) : 93 - 97
[50] N0337: Phase II study of capecitabine in combination with vinorelbine and trastuzumab for the first or second treatment of HER2+metastatic breast cancer
Tan, W.
Allred, J.
Salim, M.
Flynn, P.
Kugler, J. W.
Stella, P. J.
Wiesenfeld, M.
Bernath, A. M.
Fitch, T. R.
Perez, E. A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →